Based on experimental data and clinical data reporting progression of HCC after TACE,[3] it indicated that overexpression of angiogenic and growth factors induced by TACE might be associated with PD after TACE therapy.[4–6] Lenvatinib is an angiogenesis inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1–3), fibroblast growth factor receptor (FGFR1–4), KIT, and RET.[7] Lenvatinib has been demonstrated to improve outcomes for patients with liver cancer. Here, FGFR1 is linked to hepatocellular carcinoma.